Black Plague Reveals Clues for Fighting Hepatitis C

BY LAUREN SANTYE, ASSISTANT EDITOR
Anti-retroviral drug therapy may effectively treat hepatitis C-HIV coinfection.
PUBLISHED MONDAY, APRIL 4, 2016
“We are using a very special group of patients, a long-term longitudinal cohort called the Multicenter Hemophilia Cohort Study,” Sherman said. “It was a study started in the early days of the HIV epidemic. It looked at outcomes of patients with hemophilia, many of whom developed HIV and hepatitis because of blood contamination. We have obtained samples from thousands of those patients and are studying differential outcomes in terms of liver disease to determine if CCR5-delta 32 mutation provided protection in those patients. If over the next few years, we can show that CCR5 blockade protects HIV-infected people from liver disease, then we may change the entire treatment paradigm of HIV and make this part of the routine treatment of many or most patients.” 

Recommended Articles
Study finds a common assortment of reasons for non-initiation of HCV therapy, regardless of patient race or ethnicity.
Managing the risk of hepatitis C and liver disease among infants born to mothers with chronic HCV is a challenge.
HCV patients with cirrhosis and severe sepsis face elevated risk of organ failure.
Antiviral therapies are changing the clinical landscape for the treatment of HCV in developed countries.
Patient access to curative hepatitis C medications remains a challenge.
$auto_registration$